Meet the team
Hunter Grad, BHSc - Founder & CEO
Hunter Grad received his Honours Bachelor of Health Sciences at Carleton University. During his degree, he studied atherosclerosis and the synergistic role that genetics and the immune system play in its development. He spent a year at the University of Ottawa Heart Institute researching the biomechanics and genetics of proteins involved in dyslipidemia, and even more time conducting meta analyses of related research. After setting aside this passion project for two years to work in Orthopaedic surgery research at the Ottawa Hospital Research Institute, he returned his focus to it and founded Ameliogenix with the goal of developing cholesterol-lowering therapies using novel techniques.
Outside of academia, Hunter is an avid aquarist, cyclist, home chef, and outdoorsman.
Angelo Slade, PhDc - CSO
Angelo Slade is the Chief Scientific Officer of Ameliogenix and is currently finishing his PhD in Molecular Biology at Carleton University, Department of Health Sciences. His doctoral research focused on rare childhood genetic disorders with a particular focus on SIFD, and investigates the molecular mechanisms underlying their molecular dysregulation. His expertise lies in the dynamics of mRNA translation, as well as tRNA dysregulation and its downstream impact on protein synthesis. Angelo has always held a passion for translating fundamental research into innovative therapeutic applications and is looking forward to spearheading the development of next-generation therapies here at Ameliogenix.
- Scientific Advisory Board -
Coming soon